INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Research Paper

Formulation and Evaluation of Biodegradable Polymeric Nanoparticles of Doxorubicin for Targeted Cancer Therapy

Sidhanshu*, Deepak Saini

Smt. Tarawati Institute of Biomedical & Sciences, Roorkee.

ARTICLE INFO

Published: 23 Sept 2026
Keywords:
Doxorubicin; PLGA; polymeric nanoparticles; targeted drug delivery; cancer therapy; nanoparticle characterization; sustained release; nanomedicine
DOI:
10.5281/zenodo.22915511

ABSTRACT

Doxorubicin (DOX) is a widely used anthracycline anticancer agent with potent activity against several solid and hematological malignancies. Its clinical utility, however, is limited by dose-dependent toxicity, particularly cardiotoxicity, together with rapid distribution to healthy tissues and the development of resistance. Biodegradable polymeric nanoparticles provide a rational drug-delivery platform capable of protecting drug molecules, modifying pharmacokinetics, improving tumor exposure, and reducing nonspecific distribution. The present research paper describes the design and evaluation of a biodegradable polymeric nanoparticle system for doxorubicin delivery, with poly(lactic-co-glycolic acid) (PLGA) used as a representative biodegradable polymer. The proposed formulation strategy includes polymer selection, drug-polymer compatibility assessment, nanoparticle preparation, optimization of formulation variables, and physicochemical characterization. Critical quality attributes include particle size, polydispersity index (PDI), zeta potential, morphology, drug entrapment efficiency, drug loading, in-vitro drug release, release kinetics, and short-term stability. An illustrative dataset is included solely to demonstrate how experimental findings may be presented and interpreted; it is not claimed to represent laboratory-generated results. The expected formulation profile is a nanoscale, relatively uniform dispersion with sustained doxorubicin release and improved delivery characteristics compared with free drug. Such a platform may support passive tumor accumulation and can serve as a foundation for future ligand-mediated targeting and in-vivo evaluation.

INTRODUCTION

Cancer remains a major global health challenge and requires therapeutic strategies capable of maximizing antitumor activity while limiting injury to normal tissues. Conventional chemotherapy is often constrained by nonspecific biodistribution, narrow therapeutic windows,

***Corresponding Author:** Sidhanshu
Address: *Smt. Tarawati Institute Of Biomedical & Sciences, Roorkee.*
Email ✉: vikash.rke@gmail.com
Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

systemic adverse effects, and biological barriers that restrict drug exposure at tumor sites. Nanomedicine has therefore attracted substantial interest because nanoscale carriers can alter the physicochemical and pharmacokinetic behavior of conventional anticancer agents.

Doxorubicin hydrochloride is an anthracycline antibiotic and cytotoxic drug that acts primarily through DNA intercalation, inhibition of topoisomerase II, and generation of reactive oxygen species. It is used in the treatment of breast cancer, lymphomas, sarcomas, leukemias, and several other malignancies. Despite its effectiveness, cumulative cardiotoxicity is a major dose-limiting concern. Free doxorubicin also undergoes rapid distribution and clearance, and its exposure to normal tissues contributes to systemic toxicity.

Polymeric nanoparticles prepared from biodegradable polymers such as PLGA are attractive because the polymer undergoes hydrolytic degradation into lactic acid and glycolic acid, which enter normal metabolic pathways. The carrier can encapsulate or associate with a drug and release it through diffusion, polymer hydration, and polymer erosion. Particle size, surface characteristics, polymer molecular weight, drug-to-polymer ratio, surfactant concentration, and preparation conditions influence the final formulation.

Targeted delivery can be considered at two levels. Passive targeting exploits the altered vascular and lymphatic characteristics of tumors, although the enhanced permeability and retention (EPR) effect is heterogeneous in human tumors. Active targeting involves attaching ligands such as antibodies, peptides, aptamers, or receptor-binding molecules to the nanoparticle surface. The present work focuses on development and characterization of a biodegradable polymeric nanoparticle platform and provides a basis for subsequent active-targeting studies.

2. AIM AND OBJECTIVES.

Aim: To formulate and evaluate biodegradable polymeric nanoparticles of doxorubicin for improved and potentially targeted anticancer drug delivery.

- To select a suitable biodegradable polymeric carrier and establish a reproducible nanoparticle preparation method.
- To evaluate drug-polymer compatibility using suitable preformulation techniques.
- To prepare nanoparticle batches by a solvent-based or emulsion-based method and optimize critical formulation variables.
- To characterize optimized nanoparticles for particle size, PDI, zeta potential, morphology, drug entrapment efficiency, and drug loading.
- To investigate the in-vitro release profile of doxorubicin from the optimized nanoparticles.
- To fit the release data to mathematical kinetic models and identify the probable release mechanism.
- To assess preliminary physical stability and identify requirements for future in-vitro and in-vivo targeting studies.

3. MATERIALS AND METHODS

3.1 Materials

Material	Purpose
Doxorubicin hydrochloride	Model anticancer drug
PLGA	Biodegradable polymeric carrier
Polyvinyl alcohol (PVA)	Emulsifier/stabilizer
Acetone or ethyl acetate	Representative organic solvent, subject to validated method
Phosphate-buffered saline (PBS)	Release medium

Mannitol or suitable cryoprotectant	Optional lyophilization aid
Analytical-grade reagents	General laboratory use

Materials should be pharmaceutical/research grade and their certificate of analysis, molecular weight, polymer lactideglycolide ratio, and residual-solvent specifications should be recorded. Because doxorubicin is a hazardous cytotoxic drug, all preparation and analytical procedures should be performed under institutionally approved containment and waste-disposal procedures.

3.2 Preformulation Studies

Drug-polymer compatibility should be assessed before formulation. Fourier-transform infrared spectroscopy (FTIR) may be used to compare characteristic functional groups of the drug, polymer, and physical mixture. Where appropriate, differential scanning calorimetry (DSC) and/or powder X-ray diffraction (PXRD) can be used to investigate changes in thermal behavior and crystallinity. These studies help identify major chemical incompatibilities and changes in the physical state of the drug.

3.3 Preparation of Polymeric Nanoparticles

A representative nanoprecipitation/emulsion-solvent evaporation approach can be used. PLGA is dissolved in a suitable volatile organic phase and doxorubicin is incorporated using a method appropriate to its salt form and physicochemical properties. The organic phase is introduced into an aqueous PVA phase under controlled stirring or homogenization to generate an emulsion/nanodispersion. The organic solvent is removed under reduced pressure or controlled stirring, followed by collection of nanoparticles through centrifugation or an equivalent validated separation step. The particles may be washed to remove free drug and residual stabilizer and may then be redispersed or lyophilized with a suitable cryoprotectant.

Process variable	Example optimization range	Rationale
Drug:polymer ratio	1:5 to 1:20	Controls loading and release
PVA concentration	0.5–2.0% w/v	Affects particle size and stability
Organic phase volume	Method dependent	Controls precipitation/emulsification
Stirring/homogenization	Controlled, validated condition	Controls droplet/nuclei size
Processing time	Sufficient for solvent removal	Affects residual solvent and particle formation

3.4 Experimental Design

Optimization should preferably use a design-of-experiments (DoE) approach rather than changing one factor at a time. Independent variables may include drug-to-polymer ratio, stabilizer concentration, and mixing intensity, while responses may include particle size, PDI, entrapment efficiency, drug loading, and release characteristics. The final batch should be selected using predefined acceptance criteria and desirability-based optimization.

3.5 Characterization of Nanoparticles

Particle size and PDI

Dynamic light scattering (DLS) should be used after suitable dilution in a validated dispersion medium. Particle size is reported as mean diameter and PDI as a measure of distribution breadth.

Zeta potential

Electrophoretic light scattering can be used to estimate surface charge. The value provides information about electrostatic stabilization and surface properties.

Morphology

Transmission electron microscopy (TEM) or scanning electron microscopy (SEM) may be used to examine particle shape and surface morphology.

Entrapment efficiency

Nanoparticle-associated drug is separated from free drug, and doxorubicin is quantified by a validated UV-visible or chromatographic analytical method. Entrapment efficiency is calculated as: EE% = [(total drug − free drug)/total drug] × 100.

Drug loading

Drug loading is calculated as: DL% = [drug associated with nanoparticles/weight of recovered nanoparticles] × 100.

In-vitro release

A suitable dialysis or diffusion-based method can be used under sink conditions with a validated release medium and controlled temperature. Samples are withdrawn at predetermined intervals and replaced with fresh medium.

Release kinetics

Zero-order, first-order, Higuchi, and Korsmeyer–Peppas models can be compared. Model selection should consider goodness of fit and the physical plausibility of the mechanism.

Stability

Changes in appearance, particle size, PDI, zeta potential, drug content, and release behavior should be monitored under selected storage conditions.

4. RESULTS AND DISCUSSION

The following results are an illustrative example for manuscript formatting and interpretation. They must be replaced by actual experimental observations before submission as an original research article.

Parameter	Illustrative optimized value
Particle size	168 ± 7 nm
PDI	0.18 ± 0.03
Zeta potential	−21.6 ± 2.4 mV
Entrapment efficiency	82.4 ± 2.1%
Drug loading	7.9 ± 0.6%
Initial burst release	~14% at 2 h
Cumulative release	~78% at 48 h
Appearance	Uniform, free-flowing/redispersible nanoparticle dispersion

An optimized nanosystem in the approximate 100–250 nm range would generally be considered suitable for further nanomedicine investigation, although particle size alone does not establish tumor targeting. The illustrative PDI indicates a relatively narrow distribution. A negative zeta potential may contribute to colloidal stability depending on the formulation environment, but stability should be confirmed experimentally rather than inferred from zeta potential alone.

An entrapment efficiency above 80% in the illustrative dataset indicates that most of the drug

was associated with the polymeric carrier. Actual doxorubicin loading may vary substantially with formulation method because the drug is hydrophilic and its interaction with a hydrophobic polymer such as PLGA can be challenging. Double-emulsion or ion-pairing approaches may therefore be explored if the initial method gives inadequate loading.

4.1 Illustrative In-vitro Release Profile

Time (h)	Cumulative DOX release (%)
0	0
2	14
4	23
8	34
12	43
24	59
36	69
48	78

The illustrative profile demonstrates an initial limited burst followed by sustained release. The early release may be associated with drug located near or on the particle surface, whereas later release can result from diffusion through hydrated polymer domains and progressive PLGA degradation. A suitable formulation should balance sustained release with adequate drug availability; excessively slow release may reduce therapeutic exposure.

4.2 Release Kinetics

Model	Illustrative interpretation
Zero-order	Tests approximately constant release over time
First-order	Assesses release proportional to remaining drug
Higuchi	Describes diffusion-controlled release from a matrix under simplifying assumptions
Korsmeyer–Peppas	Useful for evaluating anomalous transport when applied within its valid range

Release-model fitting should be performed on the actual experimental data. The model with the best statistical fit should not automatically be interpreted as proof of mechanism; mechanistic conclusions should also consider polymer degradation, matrix structure, drug distribution, and experimental conditions.

4.3 Stability Considerations

Nanoparticles may undergo aggregation, hydrolysis, drug leakage, or changes in surface properties during storage. Lyophilization can improve long-term physical stability when an appropriate cryoprotectant and cycle are established. At minimum, stability studies should monitor particle size, PDI, zeta potential, drug content, visual appearance, and release profile. Formal stability protocols should follow applicable institutional and regulatory expectations.

4.4 Targeting Strategy and Therapeutic Rationale

Polymeric nanoparticles may improve the therapeutic index by changing drug distribution and release. Passive tumor accumulation remains a useful conceptual framework, but the EPR effect varies with tumor type, vascularity, stromal composition, and disease stage. Therefore, future development should investigate active targeting using ligands directed toward receptors overexpressed on a selected tumor type. Examples include folate-receptor, transferrin-receptor, peptide, antibody, or aptamer-based approaches. Targeting ligand density, orientation, stability, receptor specificity, and off-target uptake must be optimized. Cellular uptake alone should not be equated with therapeutic targeting; functional cytotoxicity and in-vivo biodistribution are required.

5. SCHEMATIC PLACEHOLDERS

1. Proposed nanoparticle formulation workflow

PLACEHOLDER

Drug/polymer preparation → emulsification/nanoprecipitation → solvent removal → washing → concentration → lyophilization/redispersion → characterization.

2. Conceptual nanoparticle structure

PLACEHOLDER

Schematic showing PLGA polymer matrix containing doxorubicin, stabilizer layer, and optional surface ligand for active targeting.

3. Particle-size distribution

PLACEHOLDER

Insert DLS intensity/volume distribution plot generated from the actual optimized batch.

4. In-vitro drug-release curve

PLACEHOLDER

Plot cumulative doxorubicin release (%) versus time using the actual experimental dataset.

5. Proposed mechanism of targeted delivery

PLACEHOLDER

Illustrate circulation, tumor accumulation, receptor interaction (if ligand-functionalized), cellular uptake, endosomal processing, and intracellular drug release.

6. LIMITATIONS

- The numerical results included in this manuscript are illustrative and must not be represented as experimental findings unless independently generated and verified.
- Nanoparticle size and sustained release do not by themselves establish targeted cancer therapy.
- Passive tumor accumulation is heterogeneous and cannot be assumed to occur equally in all human tumors.
- Doxorubicin loading in hydrophobic polymers can be formulation-dependent and may require specialized techniques.
- In-vitro cytotoxicity, cellular uptake, hemocompatibility, pharmacokinetics, biodistribution, efficacy, and cardiotoxicity studies are required before therapeutic conclusions can be made.

CONCLUSION

Biodegradable polymeric nanoparticles represent a promising platform for modifying the delivery of doxorubicin and potentially improving its therapeutic index. PLGA-based systems can

provide controlled drug release and tunable physicochemical characteristics while using a biodegradable carrier. The proposed development pathway combines preformulation studies, formulation optimization, nanoscale characterization, release testing, kinetic analysis, and stability assessment. The illustrative formulation profile demonstrates how an optimized nanoparticle batch may be presented in a research manuscript, but the values must be replaced with authentic experimental results. Future work should emphasize validated analytical methods, mechanistic cellular studies, active-targeting strategies, pharmacokinetic and biodistribution evaluation, antitumor efficacy, and safety assessment, particularly with respect to doxorubicin-associated cardiotoxicity.

FUTURE SCOPE

• Optimization through Quality by Design (QbD) and Design of Experiments.
• Surface functionalization with tumor-specific ligands.
• Evaluation of cellular uptake and cytotoxicity in appropriate cancer cell lines.
• Assessment of pharmacokinetics, biodistribution, tumor accumulation, and antitumor efficacy in suitable animal models.
• Investigation of combination therapy or co-delivery strategies where scientifically justified.
• Development of scalable, reproducible, and quality-controlled manufacturing processes.

DECLARATIONS

Ethics approval: Not applicable to this literature/formulation manuscript. Any future animal or human study must obtain the required institutional approvals before commencement.
Conflict of interest: The authors should declare any actual financial or personal conflicts. Suggested statement: The authors declare no conflict of interest.
Funding: No external funding is declared for this manuscript unless otherwise specified.
Data availability: Actual experimental datasets should be made available according to the target journal's policy.

REFERENCES

1. World Health Organization. Cancer. Geneva: WHO; 2024.
2. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
3. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013;65(2):157-170.
4. Carvalho C, Santos RX, Cardoso S, Correia S, Oliveira PJ, Santos MS, et al. Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem. 2009;16(25):3267-3285.
5. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505-522.
6. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel). 2011;3(3):1377-1397.
7. Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chem Rev. 2016;116(4):2602-2663.
8. Patra JK, Das G, Fraceto L, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et

al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16:71.
9. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017;17(1):20-37.
10. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-based medicines: a review of FDA-approved materials and clinical trials to date. Pharm Res. 2016;33:2373-2387.
11. Mitchell MJ, Billingsley MM, Haley RM, Wechman SL, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20:101-124.
12. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5:161-171.
13. Torchilin VP. Multifunctional, stimuli-sensitive nanoparticulate systems for drug delivery. Nat Rev Drug Discov. 2014;13:813-827.
14. Allison M. FDA approves Doxil for ovarian cancer. Nat Biotechnol. 1995;13:1443.
15. Gabizon A, Shmeeda H, Barenholz Y. Pharmacological implications of the physical properties of liposomes. Chem Phys Lipids. 2003;64:1-12.
16. Sutton D, Nasongkla N, Blanco E, Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24:1029-1046.
17. Tran S, DeGiovanni PJ, Piel B, Rai P. Cancer nanomedicine: a review of recent success in drug delivery. Clin Transl Med. 2017;6:44.
18. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33:941-951.
19. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm. 1989;55:R1-R4.
20. Müller RH, Rühl D, Runge SA. Biodegradable nanoparticles as controlled release systems. In: Benita S, editor. Microencapsulation: Methods and Industrial Applications. 2nd ed. New York: CRC Press; 2005.

HOW TO CITE: Sidhanshu, Deepak Saini, Formulation and Evaluation of Biodegradable Polymeric Nanoparticles of Doxorubicin for Targeted Cancer Therapy, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 9, 2904-2911, https://doi.org/10.5281/zenodo.22915511